Interstitial Cystitis Clinical Trial
— magicOfficial title:
Maryland Genetics of Interstitial Cystitis (MaGIC)
Verified date | March 2010 |
Source | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The cause of interstitial cystitis is unknown. However, it tends to run in some families
suggesting that there may be a genetic susceptibility to the disease. For instance, the
disease is found 17 times more commonly in first-degree relatives (parent, sibling, or child)
of patients with interstitial cystitis than in the general population. Furthermore, if one
twin has interstitial cystitis, the disease is much more common in identical co-twins than
fraternal co-twins. This evidence suggests that, in some families, genes that make a person
susceptible to interstitial cystitis are being passed from one generation to the next.
The University of Maryland School of Medicine and the National Institutes of Health are
performing a study to identify these genes for susceptibility for interstitial cystitis. This
study is entitled the Maryland Genetics of Interstitial Cystitis (MaGIC) study. The MaGIC
study will investigate several hundred families with two or more blood relatives with
interstitial cystitis. The study will seek to find changes in genes that are found far more
commonly in family members who have interstitial cystitis than in those who do not have the
disease.Identifying these genes should lead to a better understanding of the cause of
interstitial cystitis. Finding the cause is the first step to finding the cure.
This is a national study which is conducted by telephone and mail, and in which you can
participate entirely from your home.
Status | Completed |
Enrollment | 0 |
Est. completion date | November 2008 |
Est. primary completion date | |
Accepts healthy volunteers | |
Gender | All |
Age group | 13 Years and older |
Eligibility |
Inclusion Criteria: - Have interstitial cystitis, or painful bladder syndrome. - Have at least one blood relative with interstitial cystitis, painful bladder syndrome, or urinary symptoms similar to yours. - Are 13 years of age or older. - Are available for a telephone, mail, or website interview. - Live in the USA or Canada. Exclusion Criteria: - Are less than 13 years of age. - Have Parkinson's disease, Multiple Sclerosis, Spina bifida, or another neurologic disease that preceeded your interstitial cystitis symptoms |
Country | Name | City | State |
---|---|---|---|
United States | University of Maryland Interstitial Cystitis Center | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04313972 -
IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone
|
Phase 4 | |
Completed |
NCT03282318 -
A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis
|
Phase 2 | |
Completed |
NCT03463499 -
The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients
|
N/A | |
Completed |
NCT02898220 -
Trans-MAPP II Study of Urologic Chronic Pelvin Pain
|
||
Terminated |
NCT02591199 -
Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
Completed |
NCT02247557 -
Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis
|
Phase 2 | |
Active, not recruiting |
NCT01731470 -
Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
|
N/A | |
Completed |
NCT01197261 -
OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)
|
Phase 2 | |
Completed |
NCT00971568 -
Urinary Biomarkers Characteristic to Interstitial Cystitis
|
N/A | |
Completed |
NCT00527917 -
A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.
|
Phase 2 | |
Completed |
NCT00150488 -
URACYST® For the Treatment of GAG Deficient Interstitial Cystitis
|
N/A | |
Recruiting |
NCT00094874 -
Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms
|
Phase 3 | |
Terminated |
NCT00086684 -
Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis
|
Phase 4 | |
Recruiting |
NCT04845217 -
Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome
|
Phase 1/Phase 2 | |
Completed |
NCT04401176 -
Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
Recruiting |
NCT05147779 -
Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis
|
Phase 1 | |
Suspended |
NCT04450316 -
Low-dose Naltrexone for Bladder Pain Syndrome
|
Phase 2 | |
Completed |
NCT04010513 -
Hypnosis for Bladder Pain Syndrome
|
N/A | |
Completed |
NCT05179460 -
A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy
|
||
Completed |
NCT02232282 -
Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial
|
N/A |